Evidence map›Paper›PMID 25373478›Full record

ReviewCurrent topics in medicinal chemistry2014

Statistical analysis, optimization, and prioritization of virtual screening parameters for zinc enzymes including the anthrax toxin lethal factor.

Kimberly M Maize, Xia Zhang, Elizabeth Ambrose Amin

Abstract readReview
In one paragraph

Review in Current topics in medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kimberly M Maize
Xia Zhang
Elizabeth Ambrose AminDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55416 USA. eamin@umn.edu.
Institute of Medicinal Plant Development · CNUniversity of Minnesota · US

Funding

Anthrax Toxin Lethal Factor Inhibition StudyR01AI083234 · NIAID · UNIVERSITY OF MINNESOTA · PI AMBROSE, ELIZABETH ANN · 2009 to 2012
$1.9M
NIAID NIH HHS R01 AI083234
6 · The paper itself

Abstract

The anthrax toxin lethal factor (LF) and matrix metalloproteinase-3 (MMP-3, stromelysin-1) are popular zinc metalloenzyme drug targets, with LF primarily responsible for anthrax-related toxicity and host death, while MMP-3 is involved in cancer- and rheumatic disease-related tissue remodeling. A number of in silico screening techniques, most notably docking and scoring, have proven useful for identifying new potential drug scaffolds targeting LF and MMP-3, as well as for optimizing lead compounds and investigating mechanisms of action. However, virtual screening outcomes can vary significantly depending on the specific docking parameters chosen, and systematic statistical significance analyses are needed to prioritize key parameters for screening small molecules against these zinc systems. In the current work, we present a series of chi-square statistical analyses of virtual screening outcomes for cocrystallized LF and MMP-3 inhibitors docked into their respective targets, evaluated by predicted enzyme-inhibitor dissociation constant and root-mean-square deviation (RMSD) between predicted and experimental bound configurations, and we present a series of preferred parameters for use with these systems in the industry-standard Surflex-Dock screening program, for use by researchers utilizing in silico techniques to discover and optimize new scaffolds.

Indexed as

AnthraxAntidotesAntigens, BacterialBacillus anthracisBacterial ToxinsCatalytic DomainHigh-Throughput Screening AssaysHumansMatrix Metalloproteinase 3Matrix Metalloproteinase InhibitorsMolecular Docking SimulationResearch DesignUser-Computer InterfaceZincanthrax toxinAntidotesAntigens, BacterialBacterial ToxinsMatrix Metalloproteinase 3Matrix Metalloproteinase InhibitorsZinc

Identifiers

PMID25373478
PMCPMC4631255
OpenAlexW2055215524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.